[HTML][HTML] Mapping factors that affect the uptake of digital therapeutics within health systems: scoping review

R van Kessel, A Roman-Urrestarazu… - Journal of Medical …, 2023 - jmir.org
Background Digital therapeutics are patient-facing digital health interventions that can
significantly alter the health care landscape. Despite digital therapeutics being used to …

A systematic review of digital technology to evaluate motor function and disease progression in motor neuron disease

E Beswick, T Fawcett, Z Hassan, D Forbes, R Dakin… - Journal of …, 2022 - Springer
Amyotrophic lateral sclerosis (ALS) is the most common subtype of motor neuron disease
(MND). The current gold-standard measure of progression is the ALS Functional Rating …

ALSFRS-R-SE: an adapted, annotated, and self-explanatory version of the revised amyotrophic lateral sclerosis functional rating scale

A Maier, M Boentert, P Reilich, S Witzel, S Petri… - … research and practice, 2022 - Springer
Abstract Background The ALS Functional Rating Scale in its revised version (ALSFRS-R) is
a disease-specific severity score that reflects motor impairment and functional deterioration …

Clinical and patient‐reported outcomes and neurofilament response during tofersen treatment in SOD1‐related ALS—A multicenter observational study over 18 …

T Meyer, P Schumann, P Weydt, S Petri… - Muscle & …, 2024 - Wiley Online Library
Abstract Introduction/Aims In amyotrophic lateral sclerosis (ALS) caused by SOD1 mutations
(SOD1‐ALS), tofersen received accelerated approval in the United States and is available …

Remote digital assessment of amyotrophic lateral sclerosis functional rating scale–a multicenter observational study

T Meyer, S Spittel, T Grehl, U Weyen… - … Lateral Sclerosis and …, 2023 - Taylor & Francis
Objective Remote self-assessment of the revised amyotrophic lateral sclerosis functional
rating scale (ALSFRS-R) using digital data capture was investigated for its feasibility as an …

Patient perspectives on digital healthcare technology in care and clinical trials for motor neuron disease: an international survey

J Helleman, B Johnson, C Holdom, E Hobson… - Journal of …, 2022 - Springer
Introduction To capture the patient's attitude toward remote monitoring of motor neuron
disease (MND) in care and clinical trials, and their concerns and preferences regarding the …

Digital endpoints in clinical trials of Alzheimer's disease and other neurodegenerative diseases: challenges and opportunities

AK Brem, S Kuruppu, C de Boer, M Muurling… - Frontiers in …, 2023 - frontiersin.org
Alzheimer's disease (AD) and other neurodegenerative diseases such as Parkinson's
disease (PD) and Huntington's disease (HD) are associated with progressive cognitive …

Outcome measures in facioscapulohumeral muscular dystrophy clinical trials

M Ghasemi, CP Emerson Jr, LJ Hayward - Cells, 2022 - mdpi.com
Facioscapulohumeral muscular dystrophy (FSHD) is a debilitating muscular dystrophy with a
variable age of onset, severity, and progression. While there is still no cure for this disease …

Use of hip-versus wrist-based actigraphy for assessing functional decline and disease progression in patients with motor neuron disease

CJ Holdom, JWJ van Unnik, RPA van Eijk… - Journal of …, 2023 - Springer
Background Actigraphy has been proposed as a measure for tracking functional decline and
disease progression in patients with Motor Neuron Disease (MND). There is, however, little …

Home-monitoring of vital capacity in people with a motor neuron disease

J Helleman, JNE Bakers, E Pirard, LH van den Berg… - Journal of …, 2022 - Springer
Background Home-monitoring of spirometry has the potential to improve care for patients
with a motor neuron disease (MND) by enabling early detection of respiratory dysfunction …